NI201500147A - Uso de pidotimod para tratar la enfermedad inflamatoria intestinal - Google Patents

Uso de pidotimod para tratar la enfermedad inflamatoria intestinal

Info

Publication number
NI201500147A
NI201500147A NI201500147A NI201500147A NI201500147A NI 201500147 A NI201500147 A NI 201500147A NI 201500147 A NI201500147 A NI 201500147A NI 201500147 A NI201500147 A NI 201500147A NI 201500147 A NI201500147 A NI 201500147A
Authority
NI
Nicaragua
Prior art keywords
pidotimod
treat inflammatory
intestinal disease
inflammatory intestinal
acceptable salt
Prior art date
Application number
NI201500147A
Other languages
English (en)
Inventor
Mailland Federico
Scarci Francesco
Caserini Maurizio
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of NI201500147A publication Critical patent/NI201500147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida al uso de pidotimod, o una sal fisiológicamente acetable del mismo, para tratar el síndrome de intestino irritable. Para el tratamiento de la presente invención pidotimod, o una sal fisiológicamente aceptable del mismo, puede administrarse por vía oral o rectal.
NI201500147A 2013-04-05 2015-10-02 Uso de pidotimod para tratar la enfermedad inflamatoria intestinal NI201500147A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/057208 WO2014161595A1 (en) 2013-04-05 2013-04-05 Use of pidotimod to treat inflammatory bowel disease

Publications (1)

Publication Number Publication Date
NI201500147A true NI201500147A (es) 2016-01-06

Family

ID=48048059

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500147A NI201500147A (es) 2013-04-05 2015-10-02 Uso de pidotimod para tratar la enfermedad inflamatoria intestinal

Country Status (18)

Country Link
US (1) US20160058739A1 (es)
EP (1) EP2981289A1 (es)
JP (1) JP6122208B2 (es)
KR (1) KR20150144743A (es)
CN (1) CN105209072A (es)
AU (1) AU2013385170A1 (es)
BR (1) BR112015025296A2 (es)
CA (1) CA2901338A1 (es)
EA (1) EA201591930A1 (es)
HK (1) HK1216150A1 (es)
MA (1) MA38455B1 (es)
MX (1) MX2015014061A (es)
NI (1) NI201500147A (es)
PH (1) PH12015502305A1 (es)
SG (1) SG11201506509TA (es)
TN (1) TN2015000433A1 (es)
UA (1) UA113467C2 (es)
WO (1) WO2014161595A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
EP1673092B1 (en) * 2003-10-17 2007-08-15 4 Aza Ip Nv Heterocycle-substituted pteridine derivatives and their use in therapy
CN101134034A (zh) * 2006-08-29 2008-03-05 江卫世 免疫促进药及其制备方法
US20090142769A1 (en) * 2007-11-29 2009-06-04 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for determining anti-TNF therapeutic response
CN101623499A (zh) * 2008-07-07 2010-01-13 杨喜鸿 抗生素和匹多莫德的药物组合物及其制备方法和药物应用
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
CN102234313B (zh) * 2011-08-16 2013-02-27 青岛康地恩药业股份有限公司 一种匹多莫德的合成方法
CN102525903B (zh) * 2012-01-20 2014-07-30 江苏吴中医药集团有限公司 一种匹多莫德的口服液体制剂

Also Published As

Publication number Publication date
PH12015502305A1 (en) 2016-02-15
SG11201506509TA (en) 2015-10-29
BR112015025296A2 (pt) 2017-07-18
JP6122208B2 (ja) 2017-04-26
KR20150144743A (ko) 2015-12-28
CA2901338A1 (en) 2014-10-09
MA38455B1 (fr) 2018-05-31
CN105209072A (zh) 2015-12-30
JP2016515591A (ja) 2016-05-30
AU2013385170A1 (en) 2015-09-24
MA38455A1 (fr) 2017-12-29
UA113467C2 (uk) 2017-01-25
WO2014161595A1 (en) 2014-10-09
HK1216150A1 (zh) 2016-10-21
TN2015000433A1 (en) 2017-01-03
US20160058739A1 (en) 2016-03-03
EA201591930A1 (ru) 2016-02-29
MX2015014061A (es) 2016-04-07
EP2981289A1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
CY1125290T1 (el) Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα
GT201600123A (es) Inhibidores de syk
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
EA201692436A1 (ru) Медицинское применение
DOP2012000312A (es) Triazolopiridinas sustituidas
CL2017003133A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
CL2016000820A1 (es) Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal
PH12017500747B1 (en) Heterocyclic compound
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
ES2571452T3 (es) Compuesto antagonista de leucotrieno B4
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
NI201500147A (es) Uso de pidotimod para tratar la enfermedad inflamatoria intestinal
NI201500146A (es) Uso de pidotimod para tratar el síndrome de intestino irritable
CL2016001361A1 (es) Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa
DOP2016000062A (es) Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt
BR112017008898A2 (pt) iminoaçúcares úteis para o tratamento de doenças virais
PE20151950A1 (es) Uso de pidotimod para tratar la enfermedad intestinal inflamatoria
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
PE20151756A1 (es) Uso de pidotimod para tratar el sindrome del intestino irritable